<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03334617</url>
  </required_header>
  <id_info>
    <org_study_id>D6185C00001</org_study_id>
    <secondary_id>2017-002208-28</secondary_id>
    <secondary_id>138050</secondary_id>
    <nct_id>NCT03334617</nct_id>
  </id_info>
  <brief_title>Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.</brief_title>
  <acronym>HUDSON</acronym>
  <official_title>An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic
      NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in
      design, allowing initial assessment of the efficacy, safety, and tolerability of multiple
      treatment arms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic
      non-small cell lung cancer (NSCLC) who have progressed on an anti-programmed cell
      death-1/anti-programmed cell death ligand 1 (anti-PD-1/PD-L1) containing therapy. This study
      is modular in design, consisting of a number of treatment cohorts, allowing evaluation of the
      efficacy, safety, and tolerability of multiple treatment arms. There is currently no
      established therapy for patients who have received immune checkpoint inhibitors and
      platinum-doublet therapies, and novel treatments are urgently needed.

      This protocol has a modular design, with the potential for future treatment arms to be added
      via protocol amendment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 18, 2017</start_date>
  <completion_date type="Anticipated">November 2, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is an open-label, multi-centre, umbrella Phase II study in patients with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy. This study is modular in design, allowing initial assessment of the efficacy, safety, and tolerability of multiple treatment arms.
Within each module, there will be treatment cohorts.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the efficacy of each treatment by evaluation of objective response rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Endpoint based on modified Response Evaluation Criteria in Solid Tumours (RECIST 1.1)
Objective response rate (ORR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) using modified RECIST 1.1 assessment for the anti-tumour activity of each therapy.</measure>
    <time_frame>Through to study completion, up to 3.5 years.</time_frame>
    <description>Assessment of the anti-tumour activity of each therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best percentage change in tumour size using modified RECIST 1.1 assessment for the anti-tumour activity of each therapy</measure>
    <time_frame>Through to study completion, up to 3.5 years.</time_frame>
    <description>Assessment of the anti-tumour activity of each therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DoR) using modified RECIST 1.1 assessment for the anti-tumour activity of each therapy.</measure>
    <time_frame>Through to study completion, up to 3.5 years</time_frame>
    <description>Assessment of the anti-tumour activity of each therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) using modified RECIST 1.1 assessment for the anti-tumour activity of each therapy.</measure>
    <time_frame>Through to study completion, up to 3.5 years.</time_frame>
    <description>Assessment of the anti-tumour activity of each therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall surival (OS)</measure>
    <time_frame>Through to study completion, up to 4.5 years.</time_frame>
    <description>Assessment of the anti-tumour activity of each therapy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of adverse events/serious adverse events to assess the safety and tolerability of each treatment</measure>
    <time_frame>Through to study completion, up to 3.5 years.</time_frame>
    <description>Physical examinations, laboratory findings, and vital signs AEs/SAEs collected throughout the study, from informed consent until the safety follow-up visit</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Durvalumab + olaparib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab given in combination with olaparib .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Durvalumab + AZD9150</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab given in combination with AZD9150.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Durvalumab + AZD6738</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab given in combination with AZD6738.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Durvalumab + vistusertib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Durvalumab given in combination with Vistusertib (AZD2014).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Durvalumab given IV at 1500 mg Q4W ±2 days</description>
    <arm_group_label>Durvalumab + olaparib</arm_group_label>
    <arm_group_label>Durvalumab + AZD9150</arm_group_label>
    <arm_group_label>Durvalumab + AZD6738</arm_group_label>
    <arm_group_label>Durvalumab + vistusertib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9150</intervention_name>
    <description>AZD9150 given IV at 200mg every other day of a 1-week lead-in period followed by QW</description>
    <arm_group_label>Durvalumab + AZD9150</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD6738</intervention_name>
    <description>AZD6738 given orally at 240mg twice daily in Cycle 0 Days 1-7, followed by 7 days on treatment in each cycle between Days 22-28</description>
    <arm_group_label>Durvalumab + AZD6738</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vistusertib</intervention_name>
    <description>Vistusertib (AZD2014) given orally at a dose of 125 mg BD on an intermittent dosing schedule of 2 days on, 5 days off</description>
    <arm_group_label>Durvalumab + vistusertib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>Olaparib (AZD2281) given orally at 300 mg BD</description>
    <arm_group_label>Durvalumab + olaparib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  At least 18 years of age at the time of signing the informed consent form.

          -  Patient must have histologically or cytologically confirmed metastatic or recurrent
             NSCLC which is progressing.

          -  Patient may be second- or later-line NSCLC patient, and must have documented
             radiological and/or clinical progression on a prior anti-PD-1/PD-L1 containing
             therapy.

          -  Suitable for a new tumour biopsy.

          -  ECOG/WHO performance status of 0 to 1, and a minimum life expectancy of 12 weeks.

          -  Patient must have at least 1 lesion, not previously irradiated, that can be accurately
             measured.

          -  Evidence of post-menopausal status or negative urinary or serum pregnancy test for
             female pre-menopausal patients.

        Exclusion Criteria:

          -  Patients whose tumour samples have targetable alterations in EGFR and/or ALK are
             excluded. In addition, patients whose tumour samples are known to have targetable
             alterations in ROS1, BRAF, MET or RET, are to be excluded.

          -  Active or prior documented autoimmune or inflammatory disorders.

          -  Active infection including hepatitis B (known positive HBV surface antigen [HBsAg]
             result), hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies).

          -  Female patients who are pregnant or breastfeeding, or male or female patients of
             reproductive potential who are not willing to employ effective birth control.

          -  Known allergy or hypersensitivity to any of the study drugs or any of the study drug
             excipients.

          -  Patient has spinal cord compression or symptomatic brain metastases.

          -  Pre-existing renal disease including glomerulonephritis, nephritic syndrome, Fanconi
             Syndrome or renal tubular acidosis.

          -  Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer
             treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Heymach, M.D, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas MD Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cancer Study Locator</last_name>
    <phone>1-877-400-4656</phone>
    <email>AstraZeneca@emergingmed.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L2P 2V3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>20927</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petach-Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2017</study_first_submitted>
  <study_first_submitted_qc>November 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>anti-PD-1/PD-L1</keyword>
  <keyword>umbrella study</keyword>
  <keyword>Durvalumab</keyword>
  <keyword>MEDI4736</keyword>
  <keyword>Olaparib</keyword>
  <keyword>AZD2281</keyword>
  <keyword>AZD9150</keyword>
  <keyword>AZD6738</keyword>
  <keyword>Vistusertib</keyword>
  <keyword>AZD2014</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Olaparib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

